[Efficacy of FAEV regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor].
OBJECTIVE
To evaluate the efficacy of floxuridine, actinomycin D, etoposide, vincristine (FAEV) regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor (GTT).


METHODS
From October 2001 to May 2004, 11 cases of high-risk drug-resistant GTT were treated with FAEV regimen. The International Federation of Gynecology and Obstetrics (FIGO) prognosis score (2000) was 7 to 13 (median 9). All patients were referred to Peking Union Medical College Hospital because of failure of chemotherapy previously. After the FAEV treatment, they were followed up for 15 to 42 months.


RESULTS
Seven cases (64%, 7/11) were cured by FAEV regimen. The median treatment course for serum human chorionic gonadotropin reaching normal level was 3. Four cases (36%, 4/11) showed drug-resistant to FAEV regimen. The major side effect of FAEV regimen was myelosuppression. Granulocyte colony stimulating factor support was needed after 98% (63/64) of the courses.


CONCLUSIONS
For those high-risk drug-resistant GTT cases, FAEV regimen could be considered as an effective choice of treatment.
Wan
Xi-run
XR
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
Xiang
Yang
Y
Yang
Xiu-yu
XY
Wu
Yu
Y
Liu
Ning
N
Chen
Ling
L
Dong
Ruo-fan
RF
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011247:Pregnancy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D018997:Chorionic Gonadotropin, beta Subunit, Human; D005467:Floxuridine; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide